Patient P-02328
Synthetic patientMETA-24 · Day 175 · 55–64 · F · baseline S14Steering view · 3DOpen companion preview
Therapy response
Declining
Tolerance
Favorable
GI state
Deteriorating
Inflammatory state
Stable
Nutritional resilience
Stable
Discontinuation risk
73%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S14
- Day 68 SC-12 recommended — Supportive Compound SC-12
- Day 69 Patient accepted — Started SC-12 in the companion
- Day 74 GI-04 recommended — GI Support Protocol GI-04
- Day 75 Patient accepted — Started GI-04 in the companion
- Day 75 GI symptom burden −13% vs expected — Supportive Compound SC-12
- Day 81 Tolerance state changed — Unstable → Improving
- Day 83 GI symptom burden −26% vs expected — GI Support Protocol GI-04
- Day 89 Tolerance state changed — Unstable → Improving
- Day 93 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 93 ME-01 recommended — Monitoring Escalation ME-01
- Day 94 Patient accepted — Started ME-01 in the companion
- Day 97 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
What changed?
Trajectory began diverging from predicted response on Day 93.
Primary contributors, last 14 days
- GI instability+7
- Treatment adherence-4
- Nutritional resilience+2
What helped?
- Supportive Compound SC-12Day 68Result: symptom burden −13%
- GI Support Protocol GI-04Day 74Result: symptom burden −26%
- Monitoring Escalation ME-01Day 93Result: deterioration detected before clinical escalation
LIFE OS recommendation
Dietary Support Protocol NP-02
57%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 64% showed improvement
- median effect visible after 10 days
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Active minutes
Wearable12 min
improving · +4.6 vs previous 14 d
Sleep duration
Wearable6.9 h
stable · -0.1 vs previous 14 d
Energy level
Daily log4.3/10
stable · -0.1 vs previous 14 d
Steps
Wearable1,052
improving · +310 vs previous 14 d
GI burden
Companion49.4/100
improving · -7.2 vs previous 14 d
Adherence
Companion44.6 %
worsening · -3.6 vs previous 14 d
Sleep quality
Wearable36.9/100
stable · +1.6 vs previous 14 d
Glucose, CGM daily mean
CGM141 mg/dL
stable · -1.0 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards failing · 33 from the failing basin, 54 from restoration.
Would help
- NP-02 Dietary Support Protocol59% improved among 32 similar · onset 10 d · confidence 70%
- CR-01 Clinician Review100% improved among 6 similar · onset 5 d · confidence 70%
- DT-01 Dosing / Timing Recommendation60% improved among 5 similar · onset 5 d · confidence 70%
- More proteinGI -5.3 next day on high-intake days · n 18
Would not help
- Keep ultra-processed lowGI +5.2 next day on high-intake days · n 22
- Keep caffeine lowGI +4.7 next day on high-intake days · n 23
- Keep simple carbs lowGI +4.4 next day on high-intake days · n 25
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Protein-5.3supporter · 95%
- Ultra-processed food+5.2detractor · 95%
- Caffeine+4.7detractor · 95%
- Simple carbohydrates+4.4detractor · 95%
- Dietary fat load+3.4detractor · 73%
- Insoluble fibre+2.7detractor · 68%
- Alcohol+1.2no signal · 26%
- Histamine load+0.8no signal · 18%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓50
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 49 and rising
- Inflammatory signalling ↓50
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 48
- Autonomic recovery ↓45
- WearableResting HR 74 bpm
- Wearable1,052 steps/day
- Drug metabolism and exposure ↑40
- DNACYP2D6 poor metabolizer → higher exposure
- Butyrate / short-chain fatty acid production ↓20
- Daily logFibre intake low in recent food logs
DNA
Fictional pharmacogenomic panel
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Poor metabolizerHigher exposure at standard dose
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 2.3 · butyrate capacity 46/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisNormal
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 47 ms
- Sleep
- 6.8 h
- Steps
- 1,714
- Resting HR
- 74 bpm
Daily log: GI score 49, nutritional resilience 49, adherence 45.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02255 | 57% | S14 | GI-04 | improved | 43 |
| P-02002 | 55% | S14 | GI-04 | improved | 47 |
| P-02108 | 52% | S14 | GI-04 | improved | 43 |
| P-02106 | 51% | S14 | GI-04 | improved | 44 |
| P-02168 | 50% | S15 | GI-04 | improved | 42 |
| P-02051 | 49% | S14 | GI-04 | improved | 45 |
| P-02504 | 49% | S14 | GI-04 | improved | 52 |
| P-02103 | 48% | S14 | GI-04 | improved | 46 |
| P-02401 | 48% | S14 | GI-04 | improved | 49 |
| P-02234 | 47% | S14 | GI-04 | improved | 36 |
| P-02410 | 47% | S01 | GI-04 | improved | 55 |
| P-02176 | 46% | S14 | GI-04 | improved | 52 |